Ryan Zeidan

Ryan Zeidan, PhD, is the President and Chief Executive Officer of Sling Therapeutics, a biopharmaceutical company focused on developing an oral small molecule treatment for thyroid eye disease (TED). He has a strong background in the pharmaceutical industry, having previously served as the Chief Development Officer at Millendo Therapeutics and held various positions at Celgene and Novartis, where he led research and development activities for late-stage assets, including those in oncology and rare diseases.123

Dr. Zeidan holds a Bachelor of Science in Chemistry and Chemical Engineering from the Massachusetts Institute of Technology and a PhD in Chemistry from the California Institute of Technology. Under his leadership, Sling Therapeutics successfully launched with a $35 million Series A financing and received FDA clearance for its investigational drug, linsitinib, which is set to enter Phase 2b clinical trials for TED.123 His work aims to significantly reduce the treatment burden for patients suffering from TED, a debilitating autoimmune condition that affects approximately 20,000 people annually in the U.S..12